{"id":250825,"date":"2022-07-25T00:00:00","date_gmt":"2022-07-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidmd0099-biopharma-neuronal-ceroid-lipofuscinosis-epidemiology-2\/"},"modified":"2026-03-31T10:38:52","modified_gmt":"2026-03-31T10:38:52","slug":"epidmd0099-biopharma-neuronal-ceroid-lipofuscinosis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0099-biopharma-neuronal-ceroid-lipofuscinosis-epidemiology-mature-markets\/","title":{"rendered":"Neuronal Ceroid Lipofuscinosis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of neuronal ceroid lipofuscinosis (<abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as changes in birth rates and population size, affect the epidemiology of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts five <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> populations as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr>.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> 1.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> 2.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> 3.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"neuronal ceroid lipofuscinosis\">NCL<\/abbr> 4.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250825","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250825\/revisions"}],"predecessor-version":[{"id":283108,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250825\/revisions\/283108"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}